# Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin

> **NCT00770302** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 34 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin

## Key facts

- **NCT ID:** NCT00770302
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2009-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770302, "Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00770302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*